CorporateBoston Scientific Crashes 16% in Worst Day Since 1998 as EP Growth Fears Spook InvestorsFeb 4
Deals & Capital MarketsBoston Scientific Pays $14.5 Billion for Penumbra, Betting Big on ThrombectomyJan 15